Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jose P. Zevallos is active.

Publication


Featured researches published by Jose P. Zevallos.


Cancer | 2015

Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: A Study of the veterans affairs health care system

Jose P. Zevallos; Christine Hartman; Jennifer R. Kramer; Erich M. Sturgis; Elizabeth Y. Chiao

Thyroid cancer incidence has increased in the last several decades and may represent either a true increase in the number of cases or increased screening. The objective of this study was to examine thyroid cancer incidence and the use of thyroid ultrasound and fine‐needle aspiration (FNA) screening in the Veterans Affairs (VA) health care system. The authors hypothesized that the incidence of thyroid cancer would correspond to increases in the use of these diagnostic modalities.


Oral Diseases | 2015

The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer

Deborah M. Winn; Yuan Chin Amy Lee; Mia Hashibe; Paolo Boffetta; Antonio Agudo; Wolfgang Ahrens; Vladimir Bencko; Simone Benhamou; Stefania Boccia; Cristina Bosetti; Paul Brennan; Hermann Brenner; Gabriella Cadoni; Xavier Castellsagué; Chu Chen; David I. Conway; Maria Paula Curado; Gypsyamber D'Souza; Luigino Dal Maso; Alexander W. Daudt; Kim De Ruyck; Brenda Diergaarde; José Eluf-Neto; Eleonora Fabianova; Leticia Fernandez; Silvia Franceschi; Maura L. Gillison; Robert I. Haddad; Richard B. Hayes; Claire M. Healy

The International Head and Neck Cancer Epidemiology (INHANCE) consortium is a collaboration of research groups leading large epidemiology studies to improve the understanding of the causes and mechanisms of head and neck cancer. The consortium includes investigators of 35 studies who have pooled their data on 25 500 patients with head and neck cancer (i.e., cancers of the oral cavity, oropharynx, hypopharynx, and larynx) and 37 100 controls. The INHANCE analyses have confirmed that tobacco use and alcohol intake are key risk factors of these diseases and have provided precise estimates of risk and dose response, the benefit of quitting, and the hazard of smoking even a few cigarettes per day. Other risk factors include short height, lean body mass, low education and income, and a family history of head and neck cancer. Risk factors are generally similar for oral cavity, pharynx, and larynx, although the magnitude of risk may vary. Some major strengths of pooling data across studies include more precise estimates of risk and the ability to control for potentially confounding factors and to examine factors that may interact with each other. The INHANCE consortium provides evidence of the scientific productivity and discoveries that can be obtained from data pooling projects.


American Journal of Epidemiology | 2016

Smokeless tobacco use and the risk of head and neck cancer: Pooled analysis of US studies in the inhance consortium

Annah Wyss; Mia Hashibe; Yuan Chin Amy Lee; Shu Chun Chuang; Joshua E. Muscat; Chu Chen; Stephen M. Schwartz; Elaine M. Smith; Zuo-Feng Zhang; Hal Morgenstern; Qingyi Wei; Guojun Li; Karl T. Kelsey; Michael D. McClean; Deborah M. Winn; Stimson P. Schantz; Guo Pei Yu; Maura L. Gillison; Jose P. Zevallos; Paolo Boffetta; Andrew F. Olshan

Previous studies on smokeless tobacco use and head and neck cancer (HNC) have found inconsistent and often imprecise estimates, with limited control for cigarette smoking. Using pooled data from 11 US case-control studies (1981-2006) of oral, pharyngeal, and laryngeal cancers (6,772 cases and 8,375 controls) in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium, we applied hierarchical logistic regression to estimate odds ratios and 95% confidence intervals for ever use, frequency of use, and duration of use of snuff and chewing tobacco separately for never and ever cigarette smokers. Ever use (versus never use) of snuff was strongly associated with HNC among never cigarette smokers (odds ratio (OR) = 1.71, 95% confidence interval (CI): 1.08, 2.70), particularly for oral cavity cancers (OR = 3.01, 95% CI: 1.63, 5.55). Although ever (versus never) tobacco chewing was weakly associated with HNC among never cigarette smokers (OR = 1.20, 95% CI: 0.81, 1.77), analyses restricted to cancers of the oral cavity showed a stronger association (OR = 1.81, 95% CI: 1.04, 3.17). Few or no associations between each type of smokeless tobacco and HNC were observed among ever cigarette smokers, possibly reflecting residual confounding by smoking. Smokeless tobacco use appears to be associated with HNC, especially oral cancers, with snuff being more strongly associated than chewing tobacco.


Oral Oncology | 2016

Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents

Gypsyamber D'Souza; Devasena Anantharaman; Tarik Gheit; Behnoush Abedi-Ardekani; Daniel C. Beachler; David I. Conway; Andrew F. Olshan; Victor Wünsch-Filho; Tatiana Natasha Toporcov; Wolfgang Ahrens; Kathy Wisniewski; Franco Merletti; Stefania Boccia; Eloiza Helena Tajara; Jose P. Zevallos; José Eduardo Levi; Mark C. Weissler; Sylvia Wright; Ghislaine Scelo; Angela L. Mazul; Massimo Tommasino; Paul Brennan

OBJECTIVES To explore whether HPV-related biomarkers predict oropharyngeal squamous cell cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic utility among non-oropharyngeal (non-OP) head and neck cancers. METHODS Data from 1362 head and neck SCC (HNSCC) diagnosed 2002-2011 was used from epidemiologic studies in: Brazil (GENCAPO study, n=388), U.S. (CHANCE study, n=472), and Europe (ARCAGE study, n=502). Tumors were centrally tested for p16INK4a and HPV16 DNA (by PCR). Risk of mortality was examined using Cox proportional hazard models. RESULTS There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), ever smokers (91%), with median age of 58yearsandmedian follow-up of 3.1years (IQR=1.4-5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., p16+/HPV16+) compared to 333 HPV-unrelated (p16- and/or HPV16-) cases (HR=0.25, 95%CI=0.18-0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., Europe, and Brazil (each p⩽0.01) and after adjustment, remained significantly reduced (aHR=0.34, 95%CI=0.24-0.49). Among non-OP HNSCC, neither p16 (aHR=0.83, 95%CI=0.60-1.14), HPV16 DNA (aHR=1.20, 95%CI=0.89-1.63), or p16+/HPV16+ (aHR=0.59, 95%CI=0.32-1.08) was a significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was significantly different in OPSCC than non-OP HNSCC (p-interaction=0.02). CONCLUSION HPV-related OPSCCs had similar survival benefits across these three regions. Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not be routinely done among non-OP HNSCC.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2016

Patterns of care and perioperative outcomes in transoral endoscopic surgery for oropharyngeal squamous cell carcinoma.

Jose P. Zevallos; Nandita Mitra; Samuel Swisher-McClure

Transoral endoscopic surgery is a promising new treatment for oropharyngeal squamous cell carcinoma (SCC).


Annals of Oncology | 2016

The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium

Dana Hashim; Samantha Sartori; Paul Brennan; Maria Paula Curado; Victor Wünsch-Filho; Kimon Divaris; Andrew F. Olshan; Jose P. Zevallos; Deborah M. Winn; Silvia Franceschi; Xavier Castellsagué; J Lissowska; Peter Rudnai; Keitaro Matsuo; Hal Morgenstern; C. Chen; Thomas L. Vaughan; J. N. Hofmann; Gypsyamber D'Souza; Robert I. Haddad; H. Wu; Yuan Chin Amy Lee; Mia Hashibe; C. La Vecchia; Paolo Boffetta

BACKGROUND Poor oral hygiene has been proposed to contribute to head and neck cancer (HNC) risk, although causality and independency of some indicators are uncertain. This study investigates the relationship of five oral hygiene indicators with incident HNCs. METHODS In a pooled analysis of 8925 HNC cases and 12 527 controls from 13 studies participating in the International Head and Neck Cancer Epidemiology Consortium, comparable data on good oral hygiene indicators were harmonized. These included: no denture wear, no gum disease (or bleeding), <5 missing teeth, tooth brushing at least daily, and visiting a dentist ≥once a year. Logistic regression was used to estimate the effects of each oral hygiene indicator and cumulative score on HNC risk, adjusting for tobacco smoking and alcohol consumption. RESULTS Inverse associations with any HNC, in the hypothesized direction, were observed for <5 missing teeth [odds ratio (OR) = 0.78; 95% confidence interval (CI) 0.74, 0.82], annual dentist visit (OR = 0.82; 95% CI 0.78, 0.87), daily tooth brushing (OR = 0.83, 95% CI 0.79, 0.88), and no gum disease (OR = 0.94; 95% CI 0.89, 0.99), and no association was observed for wearing dentures. These associations were relatively consistent across specific cancer sites, especially for tooth brushing and dentist visits. The population attributable fraction for ≤ 2 out of 5 good oral hygiene indicators was 8.9% (95% CI 3.3%, 14%) for oral cavity cancer. CONCLUSION Good oral hygiene, as characterized by few missing teeth, annual dentist visits, and daily tooth brushing, may modestly reduce the risk of HNC.


Oncologist | 2015

Elderly Patients With Squamous Cell Carcinoma of the Head and Neck and the Benefit of Multimodality Therapy

Virginia A. Moye; Sindhu Chandramouleeswaran; Ni Zhao; Hyman B. Muss; Mark C. Weissler; David N. Hayes; Jose P. Zevallos

BACKGROUND Limited data are available regarding outcomes in elderly head and neck cancer patients. This retrospective study was designed to characterize head and neck cancer in geriatric patients. PATIENTS AND METHODS This study included all patients in a large university-based tumor registry who were diagnosed with head and neck cancer from January 1, 1990, to December 31, 2005. Patients aged ≥70 years at the time of diagnosis were defined as older. Overall survival and progression-free survival were censored at 60 months. Survival differences were compared using the log-rank test. Hazard ratios were estimated using a Cox proportional hazards model, adjusting for potential confounders. RESULTS Of 1,598 patients identified, 1,166 patients were aged <70 years (i.e., younger) and 281 patients were aged ≥70 years (older). When controlling for possible confounders, older patients were nearly twice as likely to die within 5 years as their younger counterparts (hazard ratio: 1.92). The median life expectancy for older patients was nearly 5 years for stage I-II disease and <2 years for stage III-IV disease. Older patients with stage III-IV disease who received multimodality therapy had 5-year survival similar to that younger patients with stage III-IV disease who were treated similarly (33.2% vs. 44.0%). Older patients with stage III-IV disease who received single-modality therapy had extremely poor survival compared with all other patients (hazard ratio for progression-free survival: 1.5). CONCLUSION This study highlights the need for better understanding of the factors affecting head and neck cancer outcomes in elderly patients. Information about life expectancy in elderly head and neck cancer patients may help guide treatment decisions.


British Journal of Cancer | 2015

Vitamin E intake from natural sources and head and neck cancer risk: a pooled analysis in the International Head and Neck Cancer Epidemiology consortium

Valeria Edefonti; Mia Hashibe; Maria Parpinel; Monica Ferraroni; F. Turati; Diego Serraino; Keitaro Matsuo; Andrew F. Olshan; Jose P. Zevallos; Deborah M. Winn; Kirsten B. Moysich; Zuo-Feng Zhang; Hal Morgenstern; Fabio Levi; Karl T. Kelsey; Michael D. McClean; Cristina Bosetti; Stimson P. Schantz; Guo-Pei Yu; Paolo Boffetta; Shu Chun Chuang; Yuan Chin Amy Lee; C. La Vecchia; Adriano Decarli

Background:Evidence for the possible effect of vitamin E on head and neck cancers (HNCs) is limited.Methods:We used individual-level pooled data from 10 case–control studies (5959 cases and 12 248 controls) participating in the International Head and Neck Cancer Epidemiology (INHANCE) consortium to assess the association between vitamin E intake from natural sources and cancer of the oral cavity/pharynx and larynx. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression models applied to quintile categories of nonalcohol energy-adjusted vitamin E intake.Results:Intake of vitamin E was inversely related to oral/pharyngeal cancer (OR for the fifth vs the first quintile category=0.59, 95% CI: 0.49–0.71; P for trend <0.001) and to laryngeal cancer (OR=0.67, 95% CI: 0.54–0.83, P for trend <0.001). There was, however, appreciable heterogeneity of the estimated effect across studies for oral/pharyngeal cancer. Inverse associations were generally observed for the anatomical subsites of oral and pharyngeal cancer and within covariate strata for both sites.Conclusion:Our findings suggest that greater vitamin E intake from foods may lower HNC risk, although we were not able to explain the heterogeneity observed across studies or rule out certain sources of bias.


Cancer | 2017

Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.

Angela L. Mazul; James Taylor; Kimon Divaris; Mark C. Weissler; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Andrew F. Olshan; Jose P. Zevallos

Indicators of poor oral health, including smoking, have been associated with increased risk of head and neck squamous cell carcinoma, especially oropharyngeal squamous cell carcinoma (OPSCC), yet few studies have examined whether this association is modified by human papillomavirus (HPV) status.


British Journal of Cancer | 2016

Previous tonsillectomy modifies odds of tonsil and base of tongue cancer.

Jose P. Zevallos; Angela L. Mazul; Nidia Rodriguez; Mark C. Weissler; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; D. Neil Hayes; Andrew F. Olshan

Background:Tonsillectomy is a commonly performed surgical procedure that involves removal of the palatine tonsils. The purpose of this study is to examine the association between previous tonsillectomy and odds of oropharyngeal squamous cell carcinoma (OPSCC) in a large population-based case–control study. We hypothesise that previous tonsillectomy is associated with a decreased odds of tonsil cancer with no impact on the odds of developing base of tongue (BOT) cancer.Methods:This was a population-based, frequency-matched case–control study with multinomial logistic regression, including 1378 controls, 108 BOT cancer cases, and 198 tonsil cancer cases. Demographic and risk factor data were collected using a structured questionnaire during an in-home visit conducted by trained nurse-interviewers. The human papillomavirus (HPV) tumour status was determined through Luminex-based multiplex PCR and p16 status by immunohistochemistry.Results:Previous tonsillectomy was associated with a nearly two-fold increased odds of BOT cancer (OR=1.95, 95% CI 1.25–3.06, P=0.003) and a large decrease in the odds of tonsil cancer (OR=0.22, 95% CI 0.13–0.36, P<0.001). When HPV status was considered, tonsillectomy was associated with a decreased odds of HPV-positive tonsil cancer (OR=0.17, 95% CI 0.08–0.34, P<0.001) and an increased risk of HPV-positive BOT cancer (OR=2.46, 95% CI 1.22–4.95, P=0.012). When p16 status was considered, tonsillectomy was associated with an increased odds of p16-positive BOT cancer (OR=2.24, 95% CI 1.16–4.35, P=0.017) and a decreased odds of p16-positive tonsil cancer (OR=0.14, 95% CI 0.07–0.31, P<0.001).Conclusions:Previous tonsillectomy modifies the odds of both tonsil and BOT cancer, with decreased odds of tonsil cancer and increased odds of BOT cancer. A history of previous tonsillectomy may play a role in OPSCC risk stratification when considered along with other covariates such as sexual history, smoking status, and age.

Collaboration


Dive into the Jose P. Zevallos's collaboration.

Top Co-Authors

Avatar

Andrew F. Olshan

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Mark C. Weissler

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Trevor Hackman

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Angela L. Mazul

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Adam M. Zanation

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

S. Patel

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Bhishamjit S. Chera

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Deborah M. Winn

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paolo Boffetta

Icahn School of Medicine at Mount Sinai

View shared research outputs
Researchain Logo
Decentralizing Knowledge